Medicine and Dentistry
Radiation Therapy
100%
Lung Cancer
92%
Neoplasm
50%
Non Small Cell Lung Cancer
41%
Malignant Neoplasm
32%
Pneumonia
23%
Prostate Cancer
21%
Disease
20%
Immunotherapy
20%
Cancer Radiotherapy
19%
Stereotactic Body Radiation Therapy
19%
Immune Checkpoint Inhibitor
19%
Small Cell Lung Cancer
18%
Recurrent Disease
17%
Overall Survival
16%
Metastatic Carcinoma
16%
Chemoradiotherapy
15%
Non-Small Cell Lung Cancer
15%
Thoracic Cancer
15%
Magnetic Resonance Imaging
14%
Airway Obstruction
14%
Surgery
13%
Progression Free Survival
12%
Radiation Therapy Planning
12%
Radiomics
12%
Oncology
12%
Prophylactic Cranial Irradiation
11%
Cancer Therapy
11%
Pediatrics
10%
Prognostic Factor
10%
Bone Metastasis
10%
Esophageal Cancer
10%
Patient-Reported Outcome
10%
Esophagus
9%
Gastroesophageal Junction
9%
Symptom
9%
Quality of Life
8%
Clinical Trial
8%
Volume CT
8%
Immune-Related Adverse Events
7%
Arm
7%
Brain Metastasis
7%
Stenting
7%
Health Care Cost
7%
Cancer Cell
7%
Retrospective Study
6%
Nivolumab
6%
Adverse Event
6%
Systemic Therapy
6%
Bronchoscopy
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
36%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
26%
Lung Cancer
26%
Immune Checkpoint Inhibitors
21%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
20%
Checkpoint Inhibitor Pneumonitis
17%
Prophylactic Cranial Irradiation
17%
Overall Survival
15%
Malignant Airway Obstruction
15%
Radiotherapy
15%
Small Cell Lung Cancer
12%
Hippocampal Sparing
10%
Neoadjuvant
10%
4D-MRI
10%
Definitive Chemoradiation
10%
Gastroesophageal Junction Cancer
10%
Tumor
8%
Immune-related Adverse Events
8%
Risk Factors
8%
Combined Modality Therapy
7%
Clinical Outcomes
7%
Pneumonitis
6%
Airway Stent
6%
Nivolumab
6%
Prostate Cancer Cells
6%
Chemotherapy
6%
Extracranial
6%
Brain Metastases
6%
Conventionally Fractionated
6%
Dosiomics
6%
Clinical Efficacy
6%
Hospitalization
6%
Radiation Dose
6%
Definitive Radiotherapy
5%
Clinical Features
5%
Lung Function
5%
Lung
5%
Early Identification
5%
Lymphopenia
5%
Nodal Failure
5%
Dose Optimization
5%
Circulating Tumor DNA (ctDNA)
5%
18F-FDG PET-CT
5%
Bone Mineral Density
5%
Healthcare Expenditure
5%
Multi-centered
5%
Oligometastatic Lung Cancer
5%
Lung Mass
5%
Incidence Risk
5%
Lung Cancer Risk
5%
